Fluorouracil

vascular endothelial growth factor A ; Homo sapiens







56 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 35355718 HIF1α/VEGF Feedback Loop Contributes to 5-Fluorouracil Resistance. 2022 4
2 32190532 Poly(1-vinylimidazole) polyplexes as novel therapeutic gene carriers for lung cancer therapy. 2020 1
3 30952738 Cytoplasmic E-Cadherin Expression Is Associated With Higher Tumour Level of VEGFA, Lower Response Rate to Irinotecan-based Treatment and Poorer Prognosis in Patients With Metastatic Colorectal Cancer. 2019 Apr 1
4 31127996 Efficacy and adverse reactions of combination therapy of bevacizumab and 5-fluorouracil in patients with metastatic colon cancer. 2019 Mar-Apr 1
5 30111992 Corneal Epithelial Hyperplasia after 5-Fluorouracil Injection. 2018 Jan-Apr 2
6 30151975 Bevacizumab-enhanced antitumor effect of 5-fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2-specificity protein 1 pathway. 2018 Oct 1
7 30271631 Combined Application of Bevacizumab and Mitomycin C or Bevacizumab and 5-Fluorouracil in Experimental Glaucoma Filtration Surgery. 2018 2
8 28454454 Chemotherapy regimen based on sorafenib combined with 5-FU on HIF-1α and VEGF expression and survival in advanced gastric cancer patients. 2017 Apr 1
9 29137307 Reversal of 5-fluorouracil resistance by EGCG is mediate by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer. 2017 Oct 10 1
10 24171833 Expression of vascular endothelial growth factor (VEGF) in macrophages, fibroblasts, and endothelial cells in pterygium treated with 5-Fluorouracil. 2015 May 4
11 25707392 Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy. 2015 Oct 2
12 25995742 Polyunsaturated fatty acids augment tumoricidal action of 5-fluorouracil on gastric cancer cells by their action on vascular endothelial growth factor, tumor necrosis factor-α and lipid metabolism related factors. 2015 Apr 25 2
13 27551256 Update on Anti-Angiogenesis Therapy in Colorectal Cancer. 2015 Dec 1
14 25419401 Effect of angiogenesis inhibitor SU6668 in combination with 5-Fu on liver metastasis from transplantation tumors of human colorectal cancer in nude mice. 2014 4
15 23374220 The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. 2013 Feb 1 2
16 23508585 PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma. 2013 Dec 1
17 23645743 Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro. 2013 May 2
18 23810214 A study of the combination of triamcinolone and 5-fluorouracil in modulating keloid fibroblasts in vitro. 2013 Sep 1
19 23997941 Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer. 2013 Sep 2
20 22767582 VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. 2012 Nov 1
21 23155356 VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. 2012 2
22 23295255 Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy. 2012 1
23 23481572 Low dose chemotherapeutic drugs without overt cytotoxic effects decrease the secretion of VEGF by cultured human tumor cells: a tentative relationship between drug type and tumor cell type response. 2012-2013 1
24 20811948 Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. 2011 Feb 2
25 21057529 Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. 2011 Mar 10 1
26 21188390 Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. 2011 Feb 1
27 21555362 VEGF gene polymorphisms may be associated with an increased risk of fluorouracil-induced diarrhea. 2011 Aug 1
28 21809488 Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: an example of pazopanib complication. 2011 Feb 1
29 22066110 Up-regulation of cyclooxygenase-2-derived prostaglandin E(2) in colon cancer cells resistant to 5-fluorouracil. 2011 Aug 1
30 20568543 Effects of the combination of hyperbaric oxygen and 5-fluorouracil on proliferation and metastasis of human nasopharyngeal carcinoma CNE-2Z cells. 2010 May-Jun 1
31 19118048 rNAPc2 inhibits colorectal cancer in mice through tissue factor. 2009 Jan 1 1
32 19846936 Glutathione modulation reverses the growth-promoting effect of growth factors, improving the 5-fluorouracil antitumour response in WiDr colon cancer cells. 2009 Oct 3
33 17851877 Effect of interferon and 5-fluorouracil on serum VEGF levels in neuroendocrine tumours. 2008 1
34 18494554 A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA. 2008 May 20 2
35 18501075 Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer. 2008 Mar 1
36 18566238 Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. 2008 Jun 2
37 18641541 VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients. 2008 Aug 3
38 18814928 Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab. 2008 Nov 1
39 17522103 Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. 2007 Apr 4
40 17673469 Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP. 2007 Jul 6
41 17715009 [Biodistribution of (99m)Tc-labeled anti-VEGF mAb 5-FU loaded polylactic acid nanoparticles in human gastric carcinoma xenografts]. 2007 Aug 2
42 17786339 Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. 2007 Oct 1
43 17851795 [Study of the anti-tumor effect of anti-vascular endothelial growth factor McAb 5-fluorouracil loaded polylactic acid nanoparticles]. 2007 Sep 10
44 16809149 Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients. 2006 Apr-May 4
45 15709211 Molecular imaging of antiangiogenic agents. 2005 Feb 1
46 16101140 Circulating vascular endothelial growth factor and interferon-gamma-inducible protein-10 levels in pancreatic cancer during chemotherapy. 2005 Sep-Oct 2
47 16118771 Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. 2005 Sep 1 3
48 19956517 Thymidylate synthase, thymidine phosphorylase, VEGF and p53 protein expression in primary colorectal cancer for predicting response to 5-fluorouracil-based chemotherapy. 2005 Aug 2
49 15031593 The role of new agents in the treatment of colorectal cancer. 2004 1
50 15280064 Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation. 2004 Jul-Aug 2